Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Lars Fransecky, Walter Fiedler, Christoph Röllig, Tim Sauer, Simon Raffel, Winfried Alsdorf, Lisa Heberling, Kumaran Nagarajan, Britta Steer, Philipp Nakov, Björn Steffen, Dorothee Deckbar, Sonja Bendig, Lorenz Bastian, Martin Neumann, Monika Brueggemann, Nicola Goekbuget, Claudia D Baldus

Blood (2023) 142 (Supplement 1): 1502.

https://doi.org/10.1182/blood-2023-173937

Published: 2023

Journal Articles

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Blood (2021) 138 (Supplement 1): 2300.

https://doi.org/10.1182/blood-2021-145553

Published: 2021

Journal Articles

T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses

Leopold Sellner, MD, Peter Dreger, MD, Max Schlitt, Henrik Knecht, Dietrich Herrmann, Thomas Reigl, Adam Krejci, Vojtech Bystry, Nikos Darzentas, Michael Rieger, MD, Sascha Dietrich, MD, Thorsten Zenz, MD, Anthony D. Ho, MD, Michael Kneba, Monika Brueggemann

Blood (2015) 126 (23): 3159.

https://doi.org/10.1182/blood.V126.23.3159.3159

Published: 2015

Journal Articles

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Katrin Deiser, Felix S. Lichtenegger, Frauke Schnorfeil, Thomas Koehnke, Torben Altmann, Veit Buecklein, Andreas Moosmann, Monika Brueggemann, Beate Wagner, Wolfgang Hiddemann, Iris Bigalke, Gunnar Kvalheim, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3805.

https://doi.org/10.1182/blood.V126.23.3805.3805

Published: 2015

Journal Articles

Non-Functional ("haploinsufficient"), but Not Dominant Negative Clonal IKZF1 Deletions Confer an Adverse Prognosis in Adult BCR-ABL -Negative Acute Lymphoblastic Leukemia

Benjamin Kobitzsch, Nicola Gökbuget, MD, Stefan Schwartz, MD, Richard Reinhardt, PhD, Monika Brueggemann, Andreas Viardot, MD, Ralph Wäsch, MD PhD, Michael Starck, MD, Eckhard Thiel, MD, Dieter Hoelzer, MD, Thomas Burmeister, MD

Blood (2015) 126 (23): 2617.

https://doi.org/10.1182/blood.V126.23.2617.2617

Published: 2015

Journal Articles

Long-Term Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Achieved Minimal Residual Disease (MRD) Response Following Anti-CD19 BiTE ® Blinatumomab

Gerhard Zugmaier, Nicola Goekbuget, Andreas Viardot, Matthias Stelljes, Svenja Neumann, Heinz A. Horst, Albrecht Reichle, Reinhard Marks, Christoph Faul, Monika Brueggemann, Chris Holland, Margit Schmidt, Noemi Mergen, Marie-Elisabeth Goebeler, Hermann Einsele, Ralf C. Bargou, Max S. Topp

Blood (2014) 124 (21): 2287.

https://doi.org/10.1182/blood.V124.21.2287.2287

Published: 2014

Journal Articles

Exome Sequencing Identifies Recurring DNMT3A Mutations in Adult ETP-ALL

Martin Neumann, MD, Sandra Heesch, PhD, Cornelia Schlee, MS, Stefan Schwartz, MD, Nicola Goekbuget, MD, Dieter Hoelzer, MD, Nikola P Konstandin, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Thorsten Raff, MD, Monika Brueggemann, Wolf-Karsten Hofmann, Stefan K Bohlander, MD, Philipp A Greif, MD, Claudia D Baldus

Blood (2012) 120 (21): 1377.

https://doi.org/10.1182/blood.V120.21.1377.1377

Published: 2012

Journal Articles

Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)

Nicola Goekbuget, MD, Joachim Beck, MD, Monika Brueggemann, Thomas Burmeister, MD, Eike C. Buss, MD, Norbert Frickhofen, MD, Andreas Huettmann, MD, Anke Morgner, MD, Albrecht Reichle, Ingo Schmidt-Wolf, MD, Stefan Schwartz, MD, Hubert Serve, Prof. Dr. med., Bernd M Spriewald, MD, Michael Starck, MD, Matthias Stelljes, MD, Andreas Viardot, MD, Knut Wendelin, MD, Dieter Hoelzer, MD

Blood (2012) 120 (21): 1493.

https://doi.org/10.1182/blood.V120.21.1493.1493

Published: 2012

Journal Articles

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Blood (2012) 120 (21): 1399.

https://doi.org/10.1182/blood.V120.21.1399.1399

Published: 2012

Journal Articles

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Max S. Topp, Nicola Goekbuget, MD, Gerhard Zugmaier, Andreas Viardot, MD, Matthias Stelljes, MD, Svenja Neumann, Heinz A. Horst, Albrecht Reichle, Reinhard Marks, Christoph Faul, MD, Monika Brueggemann, Matthias Ritgen, Petra Klappers, Noemi Mergen, Marie-Elisabeth Goebeler, Hermann Einsele, Ralf Bargou

Blood (2012) 120 (21): 670.

https://doi.org/10.1182/blood.V120.21.670.670

Published: 2012

Journal Articles

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial

Max S. Topp, MD, Nicola Goekbuget, MD, Gerhard Zugmaier, MD, Andreas Viardot, MD, Matthias Stelljes, Svenja Neumann, MD, Heinz A. Horst, MD, Albrecht Reichle, MD, Reinhard E Marks, MD, Monika Brueggemann, MD, Matthias Ritgen, MD, Petra Klappers, Noemi Mergen, MD, Marie-Elisabeth Goebeler, MD, Hermann Einsele, Dieter Hoelzer, MD, Ralf Bargou, MD

Blood (2011) 118 (21): 252.

https://doi.org/10.1182/blood.V118.21.252.252

Published: 2011

Journal Articles

Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

Nicola Goekbuget, MD, Daniel Stanze, MD, Renate Arnold, Monika Brueggemann, MD, Rainer Fietkau, MD, Mathias Freund, MD, Arnold Ganser, MD, Wolf-Dieter Ludwig, Georg Maschmeyer, MD, Thorsten Raff, MD, Harald Rieder, MD, Eckhard Thiel, Hubert Serve, MD, Michael Kneba, MD, Dieter Hoelzer, MD

Blood (2011) 118 (21): 250.

https://doi.org/10.1182/blood.V118.21.250.250

Published: 2011

Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 174.

https://doi.org/10.1182/blood.V116.21.174.174

Published: 2010

Journal Articles

Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003

Dieter Hoelzer, MD, Andreas Huettmann, MD, Felix Kaul, Sebastian Irmer, Nadja Jaekel, Martin Mohren, Thomas Lipp, Knut Wedelin, Francisco de Valle, Mathias Schmid, MD, Eckhard Thiel, Prof., Dr., Dr., h.c., Monika Brueggemann, Michael Kneba, MD, PhD, Nicola Goekbuget, MD

Blood (2010) 116 (21): 170.

https://doi.org/10.1182/blood.V116.21.170.170

Published: 2010

Journal Articles

PEG-Asparaginase Intensification In Adult Acute Lymphoblastic Leukemia (ALL): Significant Improvement of Outcome with Moderate Increase of Liver Toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003

Nicola Goekbuget, MD, Anja Baumann, MD, Joachim Beck, MD, Monika Brueggemann, MD, Helmut Diedrich, MD, Andreas Huettmann, MD, Lothar Leimer, MD, Stefan Zewen, MD, Martin Mohren, MD, Albrecht Reichle, MD, Markus Schaich, MD, Kerstin Schaefer-Eckart, MD, Marc Schmalzing, MD, Mathias Schmid, MD, Hubert Serve, MD, Reingard Stuhlmann, MD, Theis H Terwey, MD, Dieter Hoelzer, MD

Blood (2010) 116 (21): 494.

https://doi.org/10.1182/blood.V116.21.494.494

Published: 2010

Journal Articles

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

Nicola Goekbuget, MD, Monika Brueggemann, MD, Renate Arnold, MD, Claus-Rainer Bartram, PhD, Rainer Fietkau, MD, Mathias Freund, MD, Arnold Ganser, MD, Michael Kneba, MD, PhD, Thomas Lipp, MD, Wolf-Dieter Ludwig, MD, Georg Maschmeyer, MD, Dorle Messerer, Thorsten Raff, MD, Harald Rieder, MD, Eckhard Thiel, Dieter Hoelzer, MD, PhD

Blood (2009) 114 (22): 90.

https://doi.org/10.1182/blood.V114.22.90.90

Published: 2009

Journal Articles

PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels

Nicola Goekbuget, MD, Anja Baumann, MD, Joachim Beck, MD, Joachim Boos, MD, PhD, Monika Brueggemann, MD, PhD, Helmut Diedrich, MD, Andreas Hüttmann, MD, Lothar Leimer, MD, Thomas Lipp, MD, Ralph Naumann, MD, PhD, Martin Mohren, MD, Albrecht Reichle, MD, PhD, Kerstin Schäfer-Eckart, MD, Marc Schmalzing, MD, Mathias Schmid, MD, PhD, Norbert Schmitz, MD, PhD, Theis Therwey, MD, Dieter Hoelzer, MD, PhD

Blood (2008) 112 (11): 302.

https://doi.org/10.1182/blood.V112.11.302.302

Published: 2008

Journal Articles

Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic Transplantation: Mediators for Gvl Effects?

Matthias Ritgen, MD, Monika Brueggemann, MD, PhD, Sebastian Boettcher, MD, Thorsten Raff, MD, Christiane Pott, MD, Michael Hallek, M.D., Michael Kneba, MD, PhD, Peter Dreger, MD

Blood (2008) 112 (11): 3503.

https://doi.org/10.1182/blood.V112.11.3503.3503

Published: 2008

Journal Articles

Sensitivity and Applicability of Six-Color Flow Cytometry Is Comparable to ASO-Primer-Real-Time PCR (RQ-PCR) for Minimal Residual Disease (MRD) Monitoring in Adult Acute Lymphoblastic Leukemia (ALL) - A Comparative Analysis in 70 Patients from the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL).

Sebastian Boettcher, MD, Sebastian Irmer, MD, Silke Lueschen, PhD, Matthias Ritgen, MD, Thorsten Raff, MD, Nicola Goekbuget, MD, Dieter Hoelzer, MD, Heinz-August Horst, MD, Michael Kneba, MD, PhD, Monika Brueggemann, MD

Blood (2006) 108 (11): 2287.

https://doi.org/10.1182/blood.V108.11.2287.2287

Published: 2006

Journal Articles

Quantitative Assessment of Circulating t(14;18) Positive Cells by RQ-PCR at Diagnosis and Follow-Up Correspond to Clinical Characteristics and Predicts Time to Treatment Failure in Follicular Lymphoma.

Christiane Pott, MD, Sebastian Boettcher, MD, Monika Brueggemann, MD, Thorsten Raff, MD, Matthias Ritgen, MD, Michael Unterhalt, MD, Martin Dreyling, MD, Wolfgang Hiddemann, MD, Eva Hoster, MS, Michael Kneba, MD

Blood (2006) 108 (11): 2414.

https://doi.org/10.1182/blood.V108.11.2414.2414

Published: 2006

NARROW

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Non-Functional ("haploinsufficient"), but Not Dominant Negative Clonal IKZF1 Deletions Confer an Adverse Prognosis in Adult BCR-ABL -Negative Acute Lymphoblastic Leukemia

Long-Term Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Achieved Minimal Residual Disease (MRD) Response Following Anti-CD19 BiTE ® Blinatumomab

Exome Sequencing Identifies Recurring DNMT3A Mutations in Adult ETP-ALL

Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial

Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003

PEG-Asparaginase Intensification In Adult Acute Lymphoblastic Leukemia (ALL): Significant Improvement of Outcome with Moderate Increase of Liver Toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels

Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic Transplantation: Mediators for Gvl Effects?

Quantitative Assessment of Circulating t(14;18) Positive Cells by RQ-PCR at Diagnosis and Follow-Up Correspond to Clinical Characteristics and Predicts Time to Treatment Failure in Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only